Genocea Biosciences Stock News

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics []

State Street Corp purchased a new stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 19,684 shares of the biotechnology companys stock, valued at approximately $46,000. Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in []

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Ch

Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that J

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2021 Results - Earnings Call Transcript

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarte

Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors

CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dos

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.